Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda. It is currently being investigated as a treatment for relapsed or refractory peripheral T-cell lymphoma.
This page contains content from the copyrighted Wikipedia article "Alisertib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
